(QLGN) – Globe Newswire
-
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
-
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
-
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
-
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
-
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
-
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
-
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
-
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
-
Qualigen Therapeutics Divests FastPack® Diagnostics Business
-
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
-
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023
-
Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
-
Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
-
Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing
-
Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL
-
Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL
-
Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office
-
Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023
-
Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference
-
Data on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal Molecules
-
Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
-
Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302
-
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications
-
Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Canc
-
Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform
-
Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
-
Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
-
Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split
-
Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
-
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
-
Qualigen Therapeutics to Present at LD Micro Main Event XV
-
Qualigen Therapeutics to Present at LD Micro Main Event XV
-
Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium
-
Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium
-
Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting
-
Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting
-
Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board
-
Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board
-
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model
-
Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model
-
Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302
-
Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302
-
Qualigen Therapeutics to Present at BIO International Convention
-
Qualigen Therapeutics to Present at BIO International Convention
-
Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials
-
Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials
-
Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex
Back to QLGN Stock Lookup
